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Abstract
Background: The present pilot study investigating the minimum dose for short-course single and double-dose treatment of
kala-azar with an apparently new liposomal formulation of amphotericin B, Fungisome, led to identification of
immunological components for early detection of success and/or failure to cure.
Methods: Patients were treated with 5, 7.5 (single-dose) and 10 mg/kg body weight (5 mg/kg double-dose) of Fungisome.
Immunological investigations involving plasma cytokines and antigen-specific lymphoproliferation and cytokine responses
from PBMCs were carried out before, 1 week after Fungisome treatment, at the time of relapse, and again after conventional
amphotericin B treatment.
Results: At 1-month follow-up all the patients showed 100% initial cure. However, total doses of 5, 7.5 and 10 mg/kg
Fungisome showed 60%, 50% and 90% cure, respectively, at 6-months posttreatment. Patients successfully cured
demonstrated downregulation of IL-12 and IL-10 in plasma, and two-fold or more elevation of IFN-c, IL-12 and TNF, and
significant down-regulation of IL-10 and TGF-b in culture supernatants 1-week posttreatment irrespective of drug-dose. A
differential immune profile, involving insignificant decline in IL-10 and IL-12 in plasma and negligible elevation of IFN-c, IL-
12 and TNF, and persistence of IL-10, despite decline in TGF-b in culture supernatants, in apparently cured individuals,
corresponded with relapse within 6-months of treatment.
Conclusion: Immunological investigations revealed significant curative and non-curative immunomodulation 1-week
posttreatment, correlating with successful cure and relapse, respectively. Although immune-correlation was dose-
independent, almost consistent curative response in patients treated with the highest dose 10 mg/kg reflected a definitive
impact of the higher-dose on the immune response.
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Introduction
Visceral leishmaniasis (VL) or kala-azar, caused by members of
Leishmania donovani complex, is the most severe form of leishman-
iasis involving uncontrolled parasitization of liver, spleen and bone
marrow. If left untreated VL is generally fatal [1]. Although the
disease is endemic in 62 countries, 90% of the estimated 500,000
new cases occur in the rural areas of India, Nepal, Bangladesh,
Sudan and Brazil [2]. Pentavalent antimonial is the standard
therapy in the endemic regions. However, in north Bihar, India,
34–65% of the VL patients are now refractory to this treatment
[3,4].
Amphotericin B (AmB) at 15–20 mg/kg body weight renders
high cure rate of,100% in the antimonial unresponsive regions of
Bihar [5]. However, serious nephrotoxicity, intravenous adminis-
tration with constant monitoring, and prolonged hospitalization
limit its use [6]. Furthermore, AmB stimulates production of
proinflammatory cytokines including TNF-a [7,8,9] which
although contributes to the antimicrobial activity of AmB also
increases its infusion related toxicities (fever, chill, and shivering)
[10]. With few satisfactory alternative therapies available,
treatment of VL is a challenging task. Liposomal amphotericin
B, Ambisome, has the highest therapeutic index of current
antileishmanial drugs and reduces the toxicities observed with free
AmB, ensuring administration of higher doses leading to short
treatment courses with reduced side effects [11]. World Health
Organization (WHO) recommends a total dose of 10–21 mg/kg of
Ambisome for the treatment of VL [12,13,14]. However, even
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with the preferential pricing for developing countries [15],
Ambisome is almost 3-fold the price of conventional AmB. To
bring down the cost, recent clinical studies to identify minimum
effective total dose showed that a single infusion of 5 or 7.5 mg/kg
would only leave a fraction (10–20%) of patients needing further
treatment [16,17,18]. Under these circumstances, an early
prediction of lack of response in this fraction of patients who
would require more drug for treatment would be desirable.
However, there is no means to predict successful cure or failure of
drug treatment in kala-azar.
Active VL is characterized by immune suppression with weak
T cell responses [19]. In vivo cytokine profile from the serum and
at the mRNA level from bone marrow, lymphoid tissues, and
splenic aspirate of patients showed mixed Th1/Th2 cytokine
response during active disease [20,21,22,23,24]. In contrast,
studies with leishmanial Ag-stimulated PBMC showed Th2-type
bias at active VL with decreased or absent IL-2 and IFN-c
production and upregulation of both IL-10 and TGF-b
[25,26,27,28,29]. With the onset of chemotherapy and cure with
sodium antimony gluconate (SAG) and AmB, upregulation of
IFN-c, and IL-12 synchronized with a decline in IL-10 and TGF-
b levels [25,26,27,28,29]. In addition to the direct antileishmanial
activity, both AmB and SAG showed in vitro immunomodulatory
activities on PBMCs resulting in decline of IL-10, with AmB
downregulating TGF-b also [29]. So a short-course therapy with
liposomal formulation of AmB that maintains the efficacy of
AmB and is non-toxic would be the ideal first line treatment for
kala-azar.
A liposomal AmB preparation, developed in India and
commercially available as Fungisome, is safe and effective for
treatment of VL [2]. As for Ambisome, Fungisome is also an
intravenous infusion, and a total dose of 15–21 mg/kg showed an
efficacy of 90.9–100% against responsive and unresponsive cases
of VL [30]. To initiate short-course therapy, we investigated
whether a relatively higher dose at a single- (5, and 7.5 mg/kg) or a
double-dose (5 mg/kg) (total 10 mg/kg) of Fungisome could be
safe and effective for therapy of kala-azar. In addition, we were
interested to investigate whether a similar modulation of cytokine
profile as observed with AmB treatment could be obtained with
Fungisome as early as 1 week after treatment to identify if possible
immunological components for early detection of successful
treatment and/or failure to cure.
Materials and Methods
Subjects
This short-course pilot study was performed between 2006 and
2008 at the School of Tropical Medicine (Kolkata, India). Patients
were mainly from endemic regions of eastern India diagnosed with
active VL. Based on the inclusion exclusion criteria (Protocol S1)
patients of all ages and both sexes were potentially eligible if they
presented the clinical symptoms of prolonged fever, hepatospleno-
megaly, and were confirmed to be VL by K39 strip test and
detection of Leishmania parasites in the splenic or bone marrow
aspirate.
Study Design
Three groups of VL patients were classified based on their
mode of treatment. Group A (n = 10) patients were categorized
for treatment (Lifecare Innovations, India) with 5 mg/kg body
weight Fungisome single-dose. Group B (n = 10) patients were
treated with Fungisome 7.5 mg/kg single-dose, and Group C
(n= 10) were treated with Fungisome 5 mg/kg62 doses on
subsequent days. 100 ml Fungisome was dissolved in 100 ml of
normal saline and infused i.v. over 2 hours. Patients were
monitored during infusion and further for 24 hours for any
adverse effects, and were discharged 1-week after treatment.
Some of the patients who suffered relapse within 6-months of
treatment were further treated with conventional AmB (Sarabhai
Piramal Pharmaceuticals, India) (total dose 20 mg/kg body
weight) by i.v. drip in dextrose solution on alternate days.
Longitudinal heparinized blood samples from the patients were
collected at different time points. Biochemical and hematological
characteristics are shown in Table S1.
Ethics review board approval and informed consent
The study was approved by the Institutional Review Board and
Ethical Committee, Calcutta School of Tropical Medicine,
Kolkata. Written informed consent was obtained from each
patient enrolled in the study. A copy of the patient consent form
was submitted to the Ethical Committee.
Leishmanial antigen (LAg) preparation
Leishmanial antigen (LAg) was prepared from promastigotes of
L. donovani (MHOM/IN/1983/AG83) as described earlier [31].
Briefly, stationary phase promastigotes harvested after the third or
fourth passages were washed four times in ice-cold 20 mM
phosphate-buffered saline (PBS, pH 7.2) and suspended in 5 mM
cold Tris-HCl buffer (pH 7.6). The suspension was vortexed six
times for 2 min each with a 10-min interval on ice and then
centrifuged at 23106g for 10 min. The crude ghost membrane
pellet obtained was resuspended in the same buffer and sonicated
on ice three times for 1 min in an ultrasonicator. The suspension
was centrifuged at 51906g for 30 min and the supernatant
containing the LAg was harvested and stored at 270uC. The
amount of protein obtained from 1-g cell pellet was ,14 mg, as
assayed by Lowry et al [32].
Proliferation assay
Heparinized blood samples for isolation of PBMCs from VL
patients, and healthy volunteers (n = 5) from the Indian Institute
of Chemical Biology (IICB), Kolkata, India (non endemic for
Author Summary
Visceral leishmaniasis (VL) is a potentially fatal disease
without treatment, characterized by prolonged fever,
enlargement of spleen and liver, anaemia and weight loss.
Treatment for VL is difficult, as it requires prolonged and
painful application of toxic drugs with adverse side effects.
It is therefore important to develop alternative satisfactory
therapies for VL. Herein, we report the efficacy of a new
liposomal formulation of amphotericin-B, Fungisome, and
the immunological changes that take place 1-week after
treatment. Patients treated with 5 and 7.5 mg/kg (single-
dose) and 10 mg/kg (5 mg/kg double-dose) of Fungisome
showed 60%, 50% and 90% successful cure at 6-month
posttreatment, respectively. Successfully cured patients
showed reduced IL-12 and IL-10 levels in the plasma and
two-fold or more increase in Th1 type-cytokines IFN-c, IL-
12 and TNF, and down-regulation of immunosuppressive
factors IL-10 and TGF-b in the culture supernatants, 1-week
after treatment independent of drug-dose. Insignificant
decrease of plasma IL-12 and IL-10, negligible increase of
Th1-cytokines, and persistence of IL-10, despite decrease in
TGF-b in culture supernatants, correlated with relapse
within 6-months of treatment. These interesting results
pave the way for further testing of this drug as a new
alternative in the chemotherapy of leishmaniasis.
Predictive Cytokine Profile and Therapy in VL
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VL), were obtained after written informed consent and was
approved by The Ethical Committee on Human Subjects, IICB.
Briefly, PBMCs isolated from the blood samples by density
sedimentation on Histopaque-1077 (Sigma-Aldrich) (4006g, 30
min at RT), were washed and resuspended in RPMI 1640
supplemented with 10% FCS (Sigma, St Louis, MO), 2 mM L-
glutamine, penicillin (100 U/ml), and streptomycin (100 mg/ml).
PBMCs (16106/ml) of VL patients were cultured in triplicates in
96-well flat-bottom tissue culture plates (Nunc) and stimulated
with and without LAg (12.5 mg/ml) for 4 days at 37uC in 95%
humidified air with 5% CO2. 1 mCi of [
3H] Thymidine (sp. act.
5 Ci/mM; Amersham Biosciences) was added to the wells and
cultured for another 18–24 hours. Thymidine uptake was
measured in a b scintillation counter (Beckman Instruments,
Fullerton, CA).
Cytokine analysis
Plasma from VL patients were collected at different time points
and stored at 220uC for cytokine analysis. PBMCs of these
patients were cultured in the presence of LAg and media as
described above. After 96 hours supernatants were collected for
cytokine analysis. To study the direct effect of AmB and
Fungisome to modulate cytokine production, PBMCs (16106/
ml) from healthy controls were incubated with various non-toxic
concentrations of AmB (0, 0.031, 0.062, 0.125, 0.25, 0.5 mg/ml)
and Fungisome (0, 0.031, 0.062, 0.125, 0.25, 0.5, 1 mg/ml) with or
without LPS (1 mg/ml) for 48 hours at 37uC in 95% humidified air
with 5% CO2. Culture supernatants were collected and stored at
270uC until use. IFN-c, IL-12 (p40), TNF and IL-10 (BD OptEIA
ELISA kit; BD Biosciences) were measured according to the
manufacturers’ instructions. For total TGF-b measurement,
culture supernatants were acidified to activate the latent TGF-b
by adding 1 N HCl for 10 min and neutralized with 1.2 N NaOH
in 0.5 M HEPES. Plasma samples were activated with 2.5 N acetic
acid in 10 M urea for 10 min and neutralized with 2.7 N NaOH in
1 M HEPES. TGF-b was captured with monoclonal anti-TGF-b1,
MAB240, and detected with biotinylated polyclonal anti-TGF-b1,
BAF240 (R&D Systems). The standard curve was prepared using
rTGF-b1 (R&D Systems) suspended in culture medium. The color
reaction was performed using avidin-HRP and tetramethylbenzi-
dine and read at OD 450 nm.
Statistical calculation
Statistical analysis was performed using the nonparametric
Wilcoxon matched pairs signed rank test for paired samples and
the Mann-Whitney U test for unpaired samples. One-way
ANOVA followed by Tukey’s multiple comparison test was
performed to assess the differences among various groups
(GraphPad Software, Inc., San Diego, CA.). P,0.05 was
considered to be significant.
Results
Response to therapy
Three groups of patients were categorized based on the mode of
treatment with Fungisome; Group A (5 mg/kg body weight single
dose, n= 10), Group B (7.5 mg/kg single dose, n= 10) and Group
C (5 mg/kg62 doses on subsequent days, n = 10). Figure 1 shows
the flow of participants through the dose finding study. Within 3
months of study initiation, 2 out of 5 patients (40%) in Group A
returned with relapse. So this dose was considered suboptimal and
the protocol was amended to continue treatment only in Group B
and C. At 1-month follow up, initial response to treatment was
noted and all the patients were considered clinically cured. Within
6-months follow-up, 5 out of 10 patients (50%) in Group B and 1
out of 10 patients (10%) in Group C (Table 1) experienced relapse.
Therefore cure rate 6-months posttreatment was 60% in Group A,
50% in Group B and 90% in Group C. The other 5 enrolled
patients in Group A, who did not receive treatment with
Fungisome, and the patients who suffered relapse in all the three
groups, were treated with conventional AmB (20 mg/kg) and were
cured. All the three doses of Fungisome were remarkably well
tolerated (Table S2).
Circulating plasma cytokines during active VL and at
posttreatment
For immunological studies two groups of patients were
categorized, responders who were successfully cured 6-months
posttreatment and non-responders who suffered relapse within 6-
months of treatment. The mean plasma cytokine levels of both
Th1-type, IFN-c, IL-12, TNF, and Th2 type immunosuppressive
cytokines IL-10 and TGF-b were elevated during active disease
(Table 2). 1-week after treatment, there was significant downreg-
ulation of IL-12 and IL-10 (P,0.005) in the responders compared
to untreated condition, however, there was no significant change
in the levels of IFN-c, TNF and TGF-b (Table 2). The fall in IL-10
in the responders was also significant (P,0.05) when compared
with non-responders 1-week posttreatment. Difference in the
cytokine levels of non-responders was significant neither at 1-week
posttreatment nor at relapse compared to untreated patients.
However, after cure with AmB there was significant downregu-
lation again restricted to IL-12 and IL-10 (P,0.05) compared to
active diseased and relapsed patients (Table 2). Although there was
a mixed Th1-Th2 type cytokine profile in the plasma of VL
patients during active disease and after treatment with Fungisome
and AmB, a significant fall in IL-10 and IL-12 in both
corresponded with cure.
Antigen-specific lymphoproliferation and Th1-type
cytokine analysis before and 1-week after Fungisome
treatment
Consistent with prior observations [19,29], VL patients at active
disease showed impaired lymphoproliferation in response to LAg-
stimulation (Table 3, Figure S1). Remarkably, 1-week after
Fungisome treatment there was significant enhancement in
lymphoproliferation in the responders of all the three groups of
patients (P,0.0001) (Table 3) especially in Group B and Group C
(P,0.05) (Figure S1). However, non-responders showed no or low
lymphoproliferation 1-week posttreatment and at the time of
relapse. Subsequent treatment with AmB (20 mg/kg) resulted in
significantly (P,0.05) increased lymphoproliferation.
LAg-stimulated cytokine production during disease demon-
strated low levels of IFN-c, IL-12 and TNF (Table 3) measured
over background levels. 1 week after Fungisome treatment there
were two or more fold increase in antigen-stimulated IFN-c
production in the responders of all the groups (P,0.05)
(Table 3), more consistent in Group C (Figure S1) when
compared with untreated patients and non-responders (Table 3).
In contrast, there was no such increase in patients who suffered
relapse 1-week posttreatment. Although there was significant
upregulation of IL-12 and TNF in the responders of all the
groups who were cured 6-months posttreatment compared to
the untreated (P#0.0006) and non-responders (P#0.005)
(Table 3) there was low or insignificant increase in these
cytokines in non-responders following treatment. Separate
analysis indicated that immunological responses were dose-
independent (Figure S1). Therefore, two or more fold upregula-
Predictive Cytokine Profile and Therapy in VL
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tion of IFN-c, IL-12 and TNF, 1 week after Fungisome
treatment, could predict successful cure at 6-months posttreat-
ment irrespective of the drug dose. At the time of relapse the
patients had moderate levels of LAg-specific IFN-c and IL-12
and low levels of TNF (Table 3), which increased significantly
(P,0.05) after completion of AmB treatment.
Figure 1. Flowchart summarizing the clinical study.
doi:10.1371/journal.pntd.0000764.g001
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Antigen-specific immunosuppressive cytokine analysis
before and 1-week after treatment with Fungisome
Though IL-10 and TGF-b are not considered typical Th2
cytokines both have been implicated as immunosuppressive factors
in human VL. Prior to treatment there were high levels of LAg-
specific IL-10 and TGF-b, calculated over background levels, in
most of the patients of all the three groups (Table 3, Figure S2).
There was significant (P,0.005) downregulation of IL-10 in the
responders of all the three groups 1-week after Fungisome
treatment compared to before treatment (Table 3) and non-
responders (P,0.05). However, there was no significant downreg-
ulation of IL-10 in the non-responders who suffered relapse.
Similarly, TGF-b levels were high prior to treatment in all the
patients. 1 week following treatment there was decline in TGF-b in
both responders and non responders, although the fall was
significant (P,0.005) only in the responders of all the groups.
Persisting levels of IL-10 and TGF-b at the time of relapse showed
significant decline following treatment with AmB.
In vitro immunomodulatory effects of Fungisome and
AmB on human PBMCs
To compare the in vitro immunomodulatory effects of
Fungisome with conventional AmB [9], PBMCs from healthy
individuals were cultured for 48 hours in the presence or absence
of LPS and various nontoxic concentrations of these drugs
(Figure 2). Although AmB significantly (P,0.05) upregulated
LPS-stimulated TNF production, Fungisome did not increase the
TNF level (Figure 2A). Unstimulated PBMCs led to the
production of high levels of TGF-b that was enhanced further in
the presence of LPS. Both AmB and Fungisome were instrumental
in significantly (P,0.01) downregulating inherent as well as LPS-
induced TGF-b production at concentrations 0.25 mg/ml and
above (Figure 2B) and LPS-stimulated IL-10 production (P,0.05)
in a dose-dependent manner (Figure 2C). The effect was more
significant (P,0.05) for Fungisome as the highest dose of the drug
could be extended to 1 mg/ml.
Discussion
The present pilot study evaluated the efficacy for short course
single- (5, and 7.5 mg/kg) and double-dose (562 mg/kg)
Fungisome treatment of kala-azar patients. Interestingly, a
differential immune profile of the patients with modulation of in
vivo and antigen-stimulated cytokine responses was observed
before and 1 week after drug treatment which correlated with
successful cure or relapse 6-months posttreatment.
Commercially available lipid formulations of AmB have largely
remedied the drawbacks of conventional AmB enabling safe and
short-duration administration of higher doses for cost-effective
treatment. A cure rate of 90.9–100% was reported for Fungisome
at 3 mg/kg for 5–7 days (total dose 14–21 mg/kg) [30]. To
establish the lower limit of efficacy and reduce treatment duration
we initiated Fungisome treatment at 5 and 7.5 mg/kg single-dose,
and 5 mg/kg double-doses (total 10 mg/kg) on consecutive days.
All the three doses of Fungisome showed an initial clinical cure of
100% at 1-month follow-up. However, total doses of 5, 7.5 and 10
mg/kg of Fungisome, showed 60%, 50% and 90% cure rate at 6-
months posttreatment. There are few reports on comparative
short-course dose-finding studies with liposomal AmB and these
show varying results [33,34,35,36], warranting further testing of
single and double-dose regimens of liposomal AmB.
It is well established that infection with L. donovani and its control
are modulated by a range of T cell responses and cytokine
network. We therefore investigated the immune environment of
the patients at 1-week posttherapy. The results interestingly throw
light on the possible mechanisms of successful cure and relapse,
despite an apparent cure. Investigation of plasma cytokines
revealed a mixed Th1–Th2 type profile in the VL patients during
active disease as observed earlier [23,24,37,38]. Interestingly, 1-
week following treatment resulted in a significant fall in the levels
of IL-10 and IL-12 corresponding with cure. Similar fall was also









Treatment withdrawn 0 0 0
Initial cure at 1 month 5 10 10
Relapse 2 5 1
Lost to follow-up 0 0 0
Definitive cure at 6-month no. (%) 3(60) 5(50) 9(90)
NOTE. Data are no. of patients, unless otherwise indicated. Group A received a
total dose of 5 mg/kg; Group B, 7.5 mg/kg; Group C, 10 mg/kg of Fungisome.
doi:10.1371/journal.pntd.0000764.t001




(n =21) 1 week after Fungisome treatment




Responders (n =13) Non-responders (n =8)
IFN-c 23.79 (2.07) 22.22 (1.79) 15.63 (2.65) 23.19 (4.6) 23.35 (2.33)
IL-12 222.8 (19.76) 107.2 (18.14)a 172.5 (25.83) 182.9 (27.20) 100.4 (19.93)a, c
TNF 19.44 (7.74) 28.22 (15.11) 17.13 (4.90) 22.36 (7.72) 11.18 (2.80)
IL-10 62.69 (6.01) 30.58 (2.65)a, b 47.69 (6.61) 48.31 (5.22) 28.50 (1.55)a, c
TGF-b 1507 (193.1) 1450 (330.8) 1700 (313.5) 1581 (393.2) 1400 (320.7)
Plasma cytokine levels were measured by ELISA from all the 3 groups of patients, before treatment, 1 week after Fungisome treatment, at the time of relapse, and again
after AmB treatment. Data are represented as mean (SEM). P values were calculated using Mann-Whitney U test for unpaired samples; P,0.05 was considered
significant.
aSignificantly different from VL patients before treatment (P,0.005).
bSignificantly different from non-responders 1 week after Fungisome treatment (P,0.05).
cSignificantly different from the time of relapse (P,0.05).
doi:10.1371/journal.pntd.0000764.t002
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observed in the cured individuals treated with conventional AmB.
High serum levels of IFN-c during active VL do not reconcile with
large parasite burdens observed in this disease. Lack of IFN-c
activity may be related to the simultaneous presence of elevated
levels of IL-10 and TGF-b, the macrophage deactivating cytokines
in human leishmaniasis [39]. The observed fall in IL-10 levels 1-
week following treatment is coincident to the control of parasite
growth lending support to an important role of this cytokine in
human VL.
Investigations on the antigen-specific cytokine production by
PBMCs showed an enhanced Th1-type response with upregulated
IFN-c, IL-12 and TNF and reduced IL-10 and TGF-b production
1 week after treatment in VL patients who were cured at 6-months
posttreatment irrespective of the drug-dose. IL-12 helps in the
expansion of IFN-c that synergistically acts with TNF-a to activate
macrophages to kill Leishmania parasites through release of NO
[40,41]. IL-10 and TGF-b neutralize the effects of IFN-c
[37,39,42] and favor survival of Leishmania by inhibiting NO
production by the macrophages [43] thus helping in disease
progression [39,44,45,46,47,48]. Patients who suffered relapse,
showed neither significant elevation of Th1 cytokines nor
downregulation of IL-10, at this time point, although TGF-b
level was reduced. This differential immune response 1 week
posttreatment between the responder and non-responder patients
further substantiates the significance of upregulation of Th1
cytokines and simultaneous downregulation of IL-10 for the
success of therapy. Further, our studies show that this polarization
occurs as early as 1 week of treatment and thus has the potential to
serve as markers to predict therapeutic success. Elevation of
antigen-specific IL-10 and TGF-b along with the Th1 cytokines at
Table 3. LAg-specific lymphoproliferation and cytokine analysis before and after treatment with Fungisome.
Before treatment (n =21) 1-week after Fungisome treatment




Responders (n=13) Non responders (n =8)
Lymphoproliferation
Stimulation index (SI) 1.20 (0.03) 1.84 (0.12)a 1.41 (0.12) b 1.37 (0.12) 2.90 (0.12)a
Cytokines (pg/ml)
IFN-c 15.35 (3.34) 60.48 (20.74)a 20.75 (4.67)b 46.25 (24.94) 60.13 (18.85)a
IL-12 34.46 (6.44) 91.03 (12.96)a 44.53 (4.48)b 58.09 (21.29) 135.05 (32.95)a
TNF 4.52 (1.68) 17.58 (3.42)a 4.91 (0.97)b 7.06 (3.32)* 19.00 (4.02)a
IL-10 58.19 (4.17) 37.86 (9.44)a 54.69 (8.31)b 52.63 (6.69) 24.22 (4.51)a
TGF-b 393.72 (60.75) 222.12 (41.31)a 258.1 (43.43) 400.30 (61.47) 208.30 (27.49)a
NOTE. Leishmania-specific cell-mediated immune response in Fungisome treated patients. PBMCs were stimulated with 12.5 mg/ml LAg for 5 days and
lymphoproliferation was measured by [3H]thymidine incorporation for the last 18–24 hours of culture. Cytokine levels were measured from supernatants of similar
cultures after 96 hours calculated over background levels from all the 3 groups, before treatment, 1 week after Fungisome treatment, at the time of relapse and again
after AmB treatment. Data are represented as mean (SEM). P values were calculated using Mann-Whitney U test for unpaired samples; P,0.05 was considered
significant.
aSignificantly different from VL patients before treatment (P,0.05).
bSignificantly different from responders 1 week after Fungisome treatment (P,0.05).
*Excluding 1 patient in Group A, who had very high level of TNF due to some unknown reason.
doi:10.1371/journal.pntd.0000764.t003
Figure 2. Ability of Fungisome and AmB to modulate TNF, TGF-b and IL-10 production of human PBMCs. PBMCs (16106) from healthy
controls were incubated with various concentrations of Fungisome and AmB with or without LPS (1 mg/ml) for 48 h at 37uC in 95% humidified air
with 5% CO2. Cytokines (A) TNF, (B) TGF-b and (C) IL-10 were measured by ELISA from supernatants. Each symbol represents mean cytokine level
(6SEM) at each dose of the drugs (n = 5). Values for p were calculated by ordinary one-way ANOVA followed by Tukey’s multiple comparison tests;
P,0.05 was considered significant. *, P,0.02–0.05; **, P,0.01.
doi:10.1371/journal.pntd.0000764.g002
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the time of relapse substantiates the significance of immunosup-
pressive activities of IL-10 and TGF-b. Conventional AmB
treatment (20 mg/kg) of relapsed patients generated a dominant
Th1-type response as observed earlier [29].
Since cure is a combinatorial effect of drug and immune status
of the host in VL, the rationale approach towards antileishmanial
chemotherapy would be to potentiate the immune functioning of
the host [49] in addition to parasite killing. Targeting of Th1 cell
mechanism increased the efficacy of AmB and permitted lower
doses to be used with comparable activities [50,51]. In addition,
our previous study revealed that AmB can downregulate IL-10
and TGF-b in the LPS-stimulated PBMCs of healthy individuals
[29]. Interestingly, in the present study similar results were
maintained by Fungisome. Simultaneous downregulation of IL-10
and TGF-b is important as their combined in vivo blockade led to
an apparent sterile immunity in mice infected with Leishmania
parasites [48]. TNF, responsible for infusion-related toxicities of
AmB (10) was increased only in the presence of AmB. No such
increase was observed with Fungisome corroborating earlier
reports [52] of reduced TNF production by lipid carriers of AmB.
The mechanism of the observed immunoenhancement in
Fungisome treated patients was due to the combined effect of
the drug’s (AmB) parasite killing effect together with unexpectedly
rapid regulation of cytokine responses. A significant downregula-
tion of IL-12 and IL-10 in the plasma, elevation of IFN-c, IL-12
and TNF, and downregulation of IL-10 and TGF-b in PBMCs, in
patients’ 1-week after treatment corresponded with successful cure
irrespective of drug dose. Negligible decline in plasma IL-12 and
IL-10 levels, negligible elevation of IFN-c, IL-12 and TNF and
persistence of IL-10, despite decline in TGF-b in culture
supernatants of apparently cured individuals, predicted disease
relapse within 6-months posttreatment. Although the immune
modulation was dose-independent, low cure rates in Group A and
B corresponded with fall in TGF-b levels without much effect on
IL-10 expression in some of the patients who eventually relapsed.
In contrast, treatment with the highest dose in Group C
simultaneously downregulated IL-10 and TGF-b, and upregulated
IFN-c, IL-12 and TNF. This dual effect might be responsible for
the successful cure, with only one relapse, in this Group.
Fungisome maintained increased immunomodulatory activity of
AmB at doses that are toxic with the conventional AmB. To
extend this clinically appealing, novel approach, studies should be
initiated with higher total doses of 10 mg/kg (5 mg/kg double-
dose) and 15 mg/kg (7.5 mg/kg double-dose) of Fungisome with
larger number of patients to better define the role of this new
liposomal AmB.
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IL-12 response in Fungisome treated VL patients. Longitudinal
samples of PBMCs were isolated from Fungisome treated patients
before the onset of treatment, 1 week after chemotherapy, at the
time of relapse and again after the completion of AmB therapy.
Three different groups were distinguished on the basis of the drug
dose. Group A (n= 5) patients were treated with a single dose of 5
mg/kg and Group B (n= 8) with 7.5 mg/kg of Fungisome,
whereas Group C (n= 8) were treated with 10 mg/kg (5 mg/kg
double dose) of Fungisome. Cells were stimulated with 12.5 mg/ml
of LAg for 5 days and lymphoproliferation was measured by [3H]
thymidine incorporation for the last 18–24 hours of culture.
Proliferation is indicated as stimulation index (SI) for each patient.
Cytokines, IFN-c and IL-12 were measured by ELISA from the
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an individual patient. Values for p were calculated using Wilcoxon
matched pairs signed rank test for paired samples; P,0.05 were
considered significant.
Found at: doi:10.1371/journal.pntd.0000764.s004 (7.08 MB TIF)
Figure S2 Leishmania specific TNF, IL-10 and TGF-b levels
before and after Fungisome treatment in VL patients. Longitudi-
nal samples of PBMCs were isolated from Fungisome treated
patients before the onset of treatment, 1 week after chemotherapy,
at the time of relapse and again after the completion of AmB
therapy. Three different groups were distinguished on the basis of
the drug dose. Group A (n = 5) were treated with a single dose of 5
mg/kg and Group B (n= 8) with 7.5 mg/kg of Fungisome,
whereas Group C (n = 8) were treated with 10 mg/kg (5 mg/kg 2)
of Fungisome. TNF, IL-10 and TGF-b were measured by ELISA
from the supernatants of cultures stimulated with LAg (12.5 mg/
ml) for 4 days. Each symbol represents an individual patient.
Values for p were calculated using Wilcoxon matched pairs signed
rank test for paired samples; P,0.05 were considered significant.
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